About this Journal Submit a Manuscript Table of Contents
Gastroenterology Research and Practice
Volume 2012 (2012), Article ID 740381, 6 pages
http://dx.doi.org/10.1155/2012/740381
Clinical Study

Impact of Lactobacillus reuteri Supplementation on Anti-Helicobacter pylori Levofloxacin-Based Second-Line Therapy

1Departement of Internal Medicine, Catholic University of Rome, 00168 Rome, Italy
2Departement of Surgery, Catholic University of Rome, 00168 Rome, Italy

Received 12 February 2012; Revised 26 March 2012; Accepted 31 March 2012

Academic Editor: Ping-I Hsu

Copyright © 2012 Veronica Ojetti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Palli, M. Menegatti, G. Masala et al., “Helicobacter pylori infection, anti-cagA antibodies and peptic ulcer: a case-control study in Italy,” Alimentary Pharmacology and Therapeutics, vol. 16, no. 5, pp. 1015–1020, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Bayerdörffer and A. Morgner, “Gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type: management of the disease,” Digestive and Liver Disease, vol. 32, no. 3, pp. 192–194, 2000. View at Scopus
  3. N. Uemura, S. Okamoto, S. Yamamoto et al., “Helicobacter pylori infection and the development of gastric cancer,” The New England Journal of Medicine, vol. 345, no. 11, pp. 784–789, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Gasbarrini, F. Franceschi, A. Armuzzi et al., “Extradigestive manifestations of Helicobacter pylori gastric infection,” Gut, vol. 45, no. 1, pp. I9–I12, 1999. View at Scopus
  5. I. Adamsson, C. E. Nord, P. Lundquist, S. Sjöstedt, and C. Edlund, “Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients,” Journal of Antimicrobial Chemotherapy, vol. 44, no. 5, pp. 629–640, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. P. Malfertheiner, F. Megraud, C. O'Morain et al., “Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report,” Gut, vol. 56, no. 6, pp. 772–781, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Di Caro, F. Franceschi, A. Mariani et al., “Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication,” Digestive and Liver Disease, vol. 41, no. 7, pp. 480–485, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. R. J. Saad, P. Schoenfeld, M. K. Hyungjin, and W. D. Chey, “Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis,” American Journal of Gastroenterology, vol. 101, no. 3, pp. 488–496, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Karatapanis, L. Skorda, S. Georgopoulos et al., “Levofloxacin-based triple therapy versus bismuth-based quadruple therapy as a second line treatment for the eradication of H. pylori infection,” Annals of Gastroenterology, vol. 22, no. 4, pp. 263–267, 2009. View at Scopus
  10. M. Romano, A. Cuomo, A. G. Gravina et al., “Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: a randomised trial,” Gut, vol. 59, no. 11, pp. 1465–1470, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. M. De Vrese, “Health benefits of probiotics and prebiotics in women,” Menopause International, vol. 15, no. 1, pp. 35–40, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Zou, J. Dong, and X. Yu, “Meta-analysis: lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication,” Helicobacter, vol. 14, no. 5, pp. 97–107, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Candelli, E. C. Nista, E. Carloni et al., “Treatment of H. pylori infection: a review,” Current Medicinal Chemistry, vol. 12, no. 4, pp. 375–384, 2005. View at Scopus
  14. B. J. Egan, M. Katicic, H. J. O'Connor, and C. A. O'Morain, “Treatment of Helicobacter pylori,” Helicobacter, vol. 12, no. 1, pp. 31–37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Aiba, N. Suzuki, A. M. A. Kabir, A. Takagi, and Y. Koga, “Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model,” American Journal of Gastroenterology, vol. 93, no. 11, pp. 2097–2101, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. C. G. Goldman, D. A. Barrado, N. Balcarce et al., “Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children,” Nutrition, vol. 22, no. 10, pp. 984–988, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. S. J. Lewis and A. R. Freedman, “Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease,” Alimentary Pharmacology and Therapeutics, vol. 12, no. 9, pp. 807–822, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Hedin, K. Whelan, and J. O. Lindsay, “Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials,” Proceedings of the Nutrition Society, vol. 66, no. 3, pp. 307–315, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Mukai, T. Asasaka, E. Sato, K. Mori, M. Matsumoto, and H. Ohori, “Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri,” FEMS Immunology and Medical Microbiology, vol. 32, no. 2, pp. 105–110, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. R. W. Jack, J. R. Tagg, and B. Ray, “Bacteriocins of gram-positive bacteria,” Microbiological Reviews, vol. 59, no. 2, pp. 171–200, 1995. View at Scopus
  21. P. Malfertheiner, F. Mégraud, C. O'Morain et al., “Current concepts in the management of Helicobacter pylori infection—the Maastricht 2-2000 Consensus Report,” Alimentary Pharmacology and Therapeutics, vol. 16, no. 2, pp. 167–180, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. E. C. Nista, M. Candelli, F. Cremonini et al., “Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial,” Alimentary Pharmacology and Therapeutics, vol. 20, no. 10, pp. 1181–1188, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Armuzzi, F. Cremonini, F. Bartolozzi et al., “The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 2, pp. 163–169, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Armuzzi, F. Cremonini, V. Ojetti et al., “Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study,” Digestion, vol. 63, no. 1, pp. 1–7, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. F. Cremonini, S. Di Caro, M. Covino et al., “Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study,” American Journal of Gastroenterology, vol. 97, no. 11, pp. 2744–2749, 2002. View at Scopus
  26. F. Canducci, A. Armuzzi, F. Cremonini et al., “A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates,” Alimentary Pharmacology and Therapeutics, vol. 14, no. 12, pp. 1625–1629, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Myllyluoma, L. Veijola, T. Ahlroos et al., “Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy—a placebo-controlled, double-blind randomized pilot study,” Alimentary Pharmacology and Therapeutics, vol. 21, no. 10, pp. 1263–1272, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Valeur, P. Engel, N. Carbajal, E. Connolly, and K. Ladefoged, “Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract,” Applied and Environmental Microbiology, vol. 70, no. 2, pp. 1176–1181, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Francavilla, E. Lionetti, S. P. Castellaneta et al., “Inhibition of Helicobacter pylori infection in humans by Lactobacillus reuteri ATCC 55730 and effect on eradication therapy: a pilot study,” Helicobacter, vol. 13, no. 2, pp. 127–134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. W. A. De Boer, J. C. Thys, T. J. Borody, D. Y. Graham, C. O'Morain, and G. N. J. Tytgat, “Proposal for use of a standard side effect scoring system in studies exploring Helicobacter pylori treatment regimens,” European Journal of Gastroenterology and Hepatology, vol. 8, no. 7, pp. 641–643, 1996. View at Scopus
  31. D. Y. Graham and P. D. Klein, “Accurate diagnosis of Helicobacter pylori: 13C-urea breath test,” Gastroenterology Clinics of North America, vol. 29, no. 4, pp. 885–893, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. R. M. Zagari, P. Pozzato, C. Martuzzi et al., “L3C-urea breath test to assess Helicobacter pylori bacterial load,” Helicobacter, vol. 10, no. 6, pp. 615–619, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Tursi, G. Brandimarte, G. M. Giorgetti, and M. E. Modeo, “Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection,” Medical Science Monitor, vol. 10, no. 12, pp. CR662–CR666, 2004. View at Scopus
  34. E. Lionetti, V. L. Miniello, S. P. Castellaneta et al., “Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial,” Alimentary Pharmacology and Therapeutics, vol. 24, no. 10, pp. 1461–1468, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. A. V. Shornikova, I. A. Casas, E. Isolauri, H. Mykkänen, and T. Vesikari, “Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children,” Journal of Pediatric Gastroenterology and Nutrition, vol. 24, no. 4, pp. 399–404, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. I. Sakamoto, M. Igarashi, K. Kimura, A. Takagi, T. Miwa, and Y. Koga, “Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans,” Journal of Antimicrobial Chemotherapy, vol. 47, no. 5, pp. 709–710, 2001. View at Scopus
  37. P. Michetti, G. Dorta, P. H. Wiesel et al., “Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans,” Digestion, vol. 60, no. 3, pp. 203–209, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Cruchet, M. C. Obregon, G. Salazar, E. Diaz, and M. Gotteland, “Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobacter pylori colonization in children,” Nutrition, vol. 19, no. 9, pp. 716–721, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Gotteland and S. Cruchet, “Suppressive effect of frequent ingestion of Lactobacillus johnsonii La1 on Helicobacter pylori colonization in asymptomatic volunteers,” Journal of Antimicrobial Chemotherapy, vol. 51, no. 5, pp. 1317–1319, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. K. Y. Wang, S. N. Li, C. S. Liu et al., “Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori,” American Journal of Clinical Nutrition, vol. 80, no. 3, pp. 737–741, 2004. View at Scopus
  41. T. Shimizu, H. Haruna, K. Hisada, and Y. Yamashiro, “Effects of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in children,” Journal of Antimicrobial Chemotherapy, vol. 50, no. 4, pp. 617–618, 2002. View at Scopus
  42. D. Pantoflickova, I. Corthésy-Theulaz, G. Dorta et al., “Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis,” Alimentary Pharmacology and Therapeutics, vol. 18, no. 8, pp. 805–813, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Gotteland, L. Poliak, S. Cruchet, and O. Brunser, “Effect of regular ingestion of Saccharomyces boulardii plus inulin or Lactobacillus acidophilus LB in children colonized by Helicobacter pylori,” Acta Paediatrica, vol. 94, no. 12, pp. 1747–1751, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. A. V. Shornikova, I. A. Casas, H. Mykkänen, E. Salo, and T. Vesikari, “Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis,” Pediatric Infectious Disease Journal, vol. 16, no. 12, pp. 1103–1107, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. B. W. Wolf, K. B. Wheeler, D. G. Ataya, and K. A. Garleb, “Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus,” Food and Chemical Toxicology, vol. 36, no. 12, pp. 1085–1094, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. P. L. Conway, S. L. Gorbach, and B. R. Goldin, “Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells,” Journal of dairy science, vol. 70, no. 1, pp. 1–12, 1987. View at Scopus
  47. C. Johnson, J. Dicksved, and H. Jonsson, “Anti Helicobacter pylori activity among lactic acid bacteria isolated from gastric biopsies and strains of Lactobacillus reuteri,” Helicobacter, vol. 8, article 473, 2003.
  48. P. Marteau and J. C. Rambaud, “Potential of using lactic acid bacteria for therapy and immunomodulation in man,” FEMS Microbiology Reviews, vol. 12, no. 1–3, pp. 207–220, 1993. View at Scopus
  49. B. C. Johnston, A. L. Supina, M. Ospina, and S. Vohra, “Probiotics for the prevention of pediatric antibiotic-associated diarrhea,” Cochrane Database of Systematic Reviews (Online), no. 2, Article ID CD004827, 2007. View at Scopus
  50. E. Myllyluoma, L. Veijola, T. Ahlroos et al., “Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy—a placebo-controlled, double-blind randomized pilot study,” Alimentary Pharmacology and Therapeutics, vol. 21, no. 10, pp. 1263–1272, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Gotteland, O. Brunser, and S. Cruchet, “Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori?” Alimentary Pharmacology and Therapeutics, vol. 23, no. 8, pp. 1077–1086, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. J. L. Tong, Z. H. Ran, J. Shen, C. X. Zhang, and S. D. Xiao, “Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy,” Alimentary Pharmacology and Therapeutics, vol. 25, no. 2, pp. 155–168, 2007. View at Publisher · View at Google Scholar · View at Scopus